TBX2

Across TCGA pan-cancer cohorts, TBX2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TBX2 data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TBX2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TBX2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

CCRCC, UCEC, and PDAC are the cancer types where TBX2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	III,IV	0.841	0.365	<.001	49	view →
UCEC	DFS	Quartile	All	0.725	1.000	.035	12	view →
PDAC	OS	Median	II,III,IV	0.645	0.957	.015	5	view →
LUAD	OS	Median	III,IV	0.367	0.800	.042	4	view →
LSCC	OS	Tertile	II,III,IV	0.874	1.000	.032	1	view →
HNSC	OS	Median	All	0.576	0.877	.036	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TBX2–CCRCC (DFS)

Open the CCRCC breakdown →